Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for osteoarthritis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoarthritis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
weeks (three doses). Co-primary end points were change from baseline to week 24 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Physical Function, and Patient's Global Assessment of OA (PGA-OA). Joint safety and neurological assessments continued throughout the 48-week study. Results: From March 2016 to December 2017, 849 patients were randomised and evaluated (placebo n=282, tanezumab 2.5 mg n=283, tanezumab 5 mg n=284). At week 24, there was a statistically (...) Full-text links Cite Abstract Objective: Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in a study with 24-week treatment and 24-week safety follow-up. Methods: This double-blind, randomised, phase III study enrolled adults in Europe and Japan with moderate-to-severe OA who had not responded to or could not tolerate standard-of-care analgesics. Patients were randomised to tanezumab 2.5 mg or 5 mg subcutaneously or matching placebo every 8
J, et al. Sports Med. 2019 May; 49(5):743-61. 6. Kolasinski SL, Neogi T, Hochberg MC, et al. Arthritis Rheumatol. 2020 Feb; 72(2):220-33. 7. McAlindon TE, Bannuru RR, Sullivan MC, et al. Osteoarthritis Cartilage. 2014 Mar; 22(3):363-88. 8. Juhl C, Christensen R, Roos EM, et al. Arthritis Rheumatol. 2014; 66(3):626-36. Tools for Practice is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD (...) Exercise for osteoarthritis pain: how strong is the evidence? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca March
an evidence- based guideline for the comprehensive management of osteoarthritis (OA) as a collabora- tion between the American College of Rheumatology (ACR) and the Arthritis Foundation, updating the 2012 ACR recommenda- tions for the management of hand, hip, and knee OA. Methods. We identified clinically relevant population, intervention, comparator, outcomes questions and critical outcomes in OA. A Literature Review T eam performed a systematic literature review to summarize evidence supporting (...) , technology, and practice. ACR recommendations are not intended to dictate payment or insurance decisions. These recommendations cannot adequately convey all uncertainties and nuances of patient care. The American College of Rheumatology is an independent, professional, medical and scientific society that does not guarantee, warrant, or endorse any commercial product or service.KOLASINSKI ET AL 2 ???| INTRODUCTION Osteoarthritis (OA) is the most common form of arthritis, affecting an estimated 302 million
PMCID: DOI: Item in Clipboard Technology-assisted Rehabilitation Following Total Knee or Hip Replacement for People With Osteoarthritis: A Systematic Review and Meta-Analysis Xia Wang et al. BMC Musculoskelet Disord . 2019 Show details BMC Musculoskelet Disord Actions , 20 (1), 506 Authors , , , , Affiliations 1 Level 10 Kolling Institute, Institute of Bone and Joint Research, Royal North Shore Hospital, University of Sydney, Reserve Road, St. Leonards, Sydney, NSW, 2065, Australia. xia.wang (...) … Show more similar articles References Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1545–1602. doi: 10.1016/S0140-6736(16)31678-6. - - - Australian Orthopaedic Association National Joint Replacement Registry . Analysis of state and territory health data all arthroplasty, annual report
Intraarticular injection of platelet-rich plasma in knee osteoarthritis: single versus triple application approach. Pilot study. To compare the clinical effectiveness of the triple intra-articular injection of platelet-rich plasma (PRP) with respect to the single injection in patients with mild osteoarthritis of the knee.A total of 35 patients with a clinical and radiographic diagnosis of osteoarthritis grade I and II were analyzed. They were randomized into two groups: single application (18 (...) ±7.3; p lt 0.05) at the end of the study. The triple application showed better improvement in the VAS (p= 0.0007) and the total WOMAC (p= 0.0209) scores when comparing the final results between groups.The triple infiltration of PRP in patients with mild knee osteoarthritis is clinically more effective than the single application at 48 weeks of follow-up.
Temporomandibular Joints with Larger-Than-Average Horizontal Condylar Angles May Be Indicative of Internal Derangement and DegenerativeJointDisease UTCAT3418, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Temporomandibular Joints with Larger-Than-Average Horizontal Condylar Angles May Be Indicative of Internal Derangement and DegenerativeJointDisease Clinical Question Are temporomandibular joints with a greater (...) -than-average horizontal condylar angle, as measured by cone-beam computed tomography, at greater risk for jointdisease in the long term? Clinical Bottom Line A greater-than-average horizontal condylar angle (HCA) is associated with degenerativejoint changes. This is supported by a retrospective study of patients with unilateral osteoarthritic joint changes. Two small studies show that a 3D reconstructed model based on CBCT is a more accurate method of measuring the HCA than 2D CBCT images. Best
Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial. Sprifermin is under investigation as a disease-modifying osteoarthritis drug.To evaluate the effects of sprifermin on changes in total femorotibial joint cartilage thickness in the more symptomatic knee of patients with osteoarthritis.FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) was a 5-year (...) Osteoarthritis Index (WOMAC) scores. The minimal clinically important difference (MCID) is unknown for the primary outcome; for total WOMAC score in patients with hip and knee osteoarthritis, the absolute MCID is 7 U (95% CI, 4 to 10 U) and the percentage MCID is 14% (95% CI, 9% to 18%).Among 549 participants (median age, 65.0 years; 379 female [69.0%]), 474 (86.3%) completed 2-year follow-up. Compared with placebo, the changes from baseline to 2 years in total femorotibial joint cartilage thickness were
Project Number: RC1154-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of intra-articular hyaluronic acid for patients with osteoarthritis of the hip or ankle joint? Key Message One systematic review (SR) on the effectiveness of hyaluronic acid for pain and discomfort associated with hip osteoarthritis and one SR for pain associated with ankle osteoarthritis were included. With respect (...) Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip or Ankle: A Review of Clinical Effectiveness Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip or Ankle: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip or Ankle: A Review of Clinical Effectiveness Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip or Ankle: A Review of Clinical Effectiveness Last updated: July 11, 2019
Intra-Articular Hyaluronic Acid for Viscosupplementation in Osteoarthritis of the Hand, Shoulder, and Temporomandibular Joint: A Review of Clinical Effectiveness and Safety Intra-Articular Hyaluronic Acid for Viscosupplementation in Osteoarthritis of the Hand, Shoulder, and Temporomandibular Joint: A Review of Clinical Effectiveness and Safety | CADTH.ca Find the information you need Intra-Articular Hyaluronic Acid for Viscosupplementation in Osteoarthritis of the Hand, Shoulder (...) , and Temporomandibular Joint: A Review of Clinical Effectiveness and Safety Intra-Articular Hyaluronic Acid for Viscosupplementation in Osteoarthritis of the Hand, Shoulder, and Temporomandibular Joint: A Review of Clinical Effectiveness and Safety Last updated: July 25, 2019 Project Number: RC1155-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of intra-articular hyaluronic acid for patients
in Osteoarthritis of the Knee: A Review of Clinical Effectiveness and Safety Last updated: June 24, 2019 Project Number: RC1136-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of intra-articular hyaluronic acid for patients with osteoarthritis of the knee joint? Key Message Evidence suggests that there may be differences in the efficacy of intraarticular hyaluronic acid for treatment (...) of knee osteoarthritis with respect to hyaluronic acid products, numbers of injection regimen, and disease severity. Intraarticular hyaluronic acid was found to be more effective with high molecular weight and biological fermented products, with 2-to-4 injection regimens, and in patients with low-to-moderate osteoarthritis. However, studies with direct head-to-head comparison are needed to confirm these findings. Between intraarticular hyaluronic acid and intraarticular corticosteroid, evidence
The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial To prospectively assess the efficacy, general safety, and joint safety of fasinumab, an anti-nerve growth factor monoclonal antibody, in osteoarthritis (OA) hip and/or knee pain.Patients with moderate-to-severe OA pain (knee or hip) and history of inadequate response or intolerance to analgesics were randomized to receive fasinumab (at 1 (...) mg, 3 mg, 6 mg, or 9 mg) or placebo every 4 weeks over 16 weeks and were followed up to week 36. Efficacy end points were the change from baseline to week 16 in the pain and physical function subscale scores of the Western Ontario and McMaster Universities OA Index (WOMAC), and patient global assessment (PGA) of OA. Joints were monitored at scheduled assessments (by plain film radiography and magnetic resonance imaging) during treatment and follow-up, and if prompted, at the time of active joint
Effects of dry needling in HIP muscles in patients with HIP osteoarthritis: A randomized controlled trial. Dry needling (DN) in active myofascial trigger points (MTrPs) is effective to reduce pain, increase range of motion (ROM) and improve physical function in different musculoskeletal disorders. However, there is a lack of studies evaluating the effects of DN in active MTrPs in hip osteoarthritis (OA).To determine the short-term effects of DN on pain, hip ROM and physical function in patients (...) with hip OA.Double-blind randomized controlled trial.Thirty patients with unilateral hip OA were randomized into two groups: DN group and sham group. Participants received three treatment sessions. The treatment was applied in active MTrPs of the iliopsoas, rectus femoris, tensor fasciae latae and gluteus minimus muscles. Pain intensity (visual analogic scale), passive hip ROM (universal goniometer and digital inclinometer) and physical function (30s chair-stand test and 20m walk test) were assessed
The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial. Late-stage isolated medial knee osteoarthritis can be treated with total knee replacement (TKR) or partial knee replacement (PKR). There is high variation in treatment choice and little robust evidence to guide selection. The Total or Partial Knee Arthroplasty Trial (TOPKAT) therefore aims to assess (...) the clinical effectiveness and cost-effectiveness of TKR versus PKR in patients with medial compartment osteoarthritis of the knee, and this represents an analysis of the main endpoints at 5 years.Our multicentre, pragmatic randomised controlled trial was done at 27 UK sites. We used a combined expertise-based and equipoise-based approach, in which patients with isolated osteoarthritis of the medial compartment of the knee and who satisfied general requirements for a medial PKR were randomly assigned (1:1
2019LancetControlled trial quality: predicted high
Surgical interventions for symptomatic mild to moderate knee osteoarthritis. Osteoarthritis affecting the knee is common and represents a continuum of disease from early cartilage thinning to full-thickness cartilage loss, bony erosion, and deformity. Many studies do not stratify their results based on the severity of the disease at baseline or recruitment.To assess the benefits and harms of surgical intervention for the management of symptomatic mild to moderate knee osteoarthritis defined (...) been restricted to the primary comparison: surgical intervention versus non-surgical intervention.A single study, included 320 participants with symptoms consistent with meniscal tear. All subjects had the meniscal tear confirmed on knee MRI and radiographic evidence of mild to moderate osteoarthritis (osteophytes, cartilage defect or joint space narrowing). Patients with severe osteoarthritis (KL grade 4) were excluded. The study compared arthroscopic partial meniscectomy and physical therapy
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. Patients with osteoarthritis (OA) may remain symptomatic with traditional OA treatments.To assess 2 subcutaneous tanezumab dosing regimens for OA.A randomized, double-blind, multicenter trial from January 2016 to May 14, 2018 (last patient visit). Patients enrolled were 18 years or older with hip or knee OA (...) , inadequate response to OA analgesics, and no radiographic evidence of prespecified joint safety conditions.Patients received by subcutaneous administration either tanezumab, 2.5 mg, at day 1 and week 8 (n = 231); tanezumab, 2.5 mg at day 1 and 5 mg at week 8 (ie, tanezumab, 2.5/5 mg; n = 233); or placebo at day 1 and week 8 (n = 232).Co-primary end points were change from baseline to week 16 in Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) Pain (0-10, no to extreme pain), WOMAC
The effectiveness of high molecular weight hyaluronic acid for knee osteoarthritis in patients in the working age: a randomised controlled trial High molecular weight (HMW) hyaluronic acid (HA) is a treatment option for knee osteoarthritis (OA). The efficacy of HMW-HA in knee OA is investigated extensively, but the effectiveness in patients in the working age is unknown. Nevertheless, the number knee OA patients in the working age is increasing. Surgical treatment options are less eligible (...) in these patients and productivity losses are high. In this study the effectiveness of intra-articular HMW-HA added to regular non-surgical usual care in everyday clinical practice (UC) compared to UC over 52 weeks in symptomatic knee OA patients in the working age was investigated.In this open labelled randomized controlled trial, subjects aged between 18 and 65 years with symptomatic knee OA (Kellgren and Lawrence I-III) were enrolled and randomized to UC + 3 weekly injections with HMW-HA (intervention) or UC
Comparison of high, medium and low mobilization forces for reducing pain and improving physical function in patients with hip osteoarthritis: Secondary analysis of a randomized controlled trial. Long-axis distraction mobilization (LADM) of the hip has been shown to reduce pain and improve physical function in hip osteoarthritis (OA). The optimal intensity of mobilization force necessary to reduce pain and improve physical function is unknown.To compare the effects on pain and physical function (...) of three different intensities of LADM mobilization force in hip OA patients.Randomized controlled trial.Sixty patients with unilateral hip OA were randomized to three groups: low, medium or high force mobilization group. Participants received three treatment sessions of LADM. Pressure pain thresholds (PPT) at hip, knee and heel, physical function (Western Ontario and McMaster Universities physical function subscale, timed up and go and 40 m self-placed walk test) and pain after the physical function
Tramadol for osteoarthritis. Tramadol is often prescribed to treat pain and is associated physical disability in osteoarthritis (OA). Due to the pharmacologic mechanism of tramadol, it may lead to fewer associated adverse effects (i.e. gastrointestinal bleeding or renal problems) compared to non-steroidal anti-inflammatory drugs (NSAIDs). This is an update of a Cochrane Review originally published in 2006.To determine the benefits and harms of oral tramadol or tramadol combined (...) and eleven studies used active controls (two trials had both placebo and active arms). The dose of tramadol ranged from 37.5 mg to 400 mg daily; all doses were pooled. Most trials were multicenter with a mean duration of two months. Participants were predominantly women with hip or knee osteoarthritis, with a mean age of 63 years and moderate to severe pain. There was a high risk of selection bias as only four trials reported both adequate sequence generation and allocation concealment. There was a low